Navigation Links
Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
Date:12/22/2009

WOODCLIFF LAKE, N.J., Dec. 22 /PRNewswire/ -- The investigational compound, eritoran tetrasodium ("eritoran," also known as E5564) appeared to be well tolerated in patients with severe sepsis in a Phase II trial published in the January issue of Critical Care Medicine, the official journal of the Society of Critical Care Medicine, the largest multiprofessional organization dedicated to ensuring excellence and consistency in the practice of critical care.

The trial evaluated two doses of eritoran, low-dose (45mg given every 12 hours for six days) and high-dose (105mg given every 12 hours for six days), along with a placebo group. Additionally, the trial, although not powered for statistical significance, evaluated the efficacy (reduction in 28-day all-cause mortality) of eritoran versus placebo.

"Currently, limited treatment options exist for severe sepsis. In this Phase II study, eritoran was well tolerated, and the adverse events were not surprising, given the significant co-morbidities commonly seen in patients with severe sepsis," said lead investigator Mark Tidswell, MD, Director, ICU Research, Baystate Medical Center, Adult Critical Care Division, in Springfield, Mass. "Although this Phase II trial was not sized to demonstrate a reduction in mortality and the observed 26.6% mortality rate for high-dose eritoran versus 33.3% for placebo (p=0.34) was not statistically significant, the data warrant further investigation of eritoran."

About the Phase II Trial

This trial of eritoran tetrasodium (E5564) was a Phase II, randomized, double-blind, placebo-controlled, multi-center, ascending-dose trial evaluating the safety and efficacy of eritoran in patients with severe sepsis. The trial, conducted in intensive care units (ICUs) in the United States and Canada, involved 300 patients randomized to three groups: 96 received placebo, 103 received eritoran low-dose (45mg given every 12 hours for si
'/>"/>

SOURCE Eisai
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
3. American Imaging Managements New Specialty Drug Program Delivers Immediate Results
4. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
5. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
6. Immucor to Announce Fiscal Second Quarter Financial Results on Wednesday, January 6, 2010
7. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
10. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/28/2015)... SAN FRANCISCO , August 28, 2015 ... is expected to reach USD 49.12 billion by 2020, ... 2020, according to a new report by Grand View ... an estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of ...
(Date:8/27/2015)... Aug. 27, 2015 Biosimilars are not ... the U.S. Food and Drug Administration (FDA) for ... in its draft guidance issued today. The FDA,s ... proposes distinguishable names, calling for biological products to ... suffix. This proposal reflects the agency,s thinking that ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Lytle LLP, one of the region,s best known law ... Court in Rochester, upheld a high-profile products liability verdict ... In its decision, the Fourth Department judicial panel found ... of Cheektowaga, NY a quadriplegic.  In making its findings, ...
... 18, 2011 The U.S. Food and Drug Administration ... (neovascular) age-related macular degeneration (AMD), a leading cause of ... older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... affects the macula, the part of the eye that ...
Cached Medicine Technology:The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman 2The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman 3FDA Approves Eylea for Eye Disorder in Older People 2
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and alcohol ... Strawbridge, gives a new approach on solutions in his new book ":Unraveling The ... and employees getting together for meaningful group meetings. "This would educate the employees ...
(Date:8/28/2015)... ... August 28, 2015 , ... The ... honoring military veterans leading in business. Mr. Troy Mizell, Chairman of the ... inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, ...
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain ... pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his ... on to earn his title of Doctor of Chiropractic from the Palmer College of ...
(Date:8/28/2015)... ... 28, 2015 , ... The Quatela Center for Plastic Surgery is excited to ... nonsurgical product approved by the Food and Drug Administration to eliminate submental fat, also ... William Koenig are among the premier cosmetic surgeons in Rochester to offer this ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... Former NFL player and Dallas Cowboy,Jason Kaiser received top ... Kaiser earned the title of,valedictorian with a GPA of ... school and in my class especially," he said. "To ... in Parker College, Kaiser played professional football,for more than ...
... less blood loss, shorter hospital stays, study finds , , ... surgery to remove pancreatic tumors or cysts leads to ... finds. , In laparoscopic surgery, doctors make smaller ... with fiber optics and video cameras. This less invasive ...
... - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial ... specified otherwise, all amounts are in U.S. dollars,and in ... of 2008, we were pleased to report the U.S. ... for blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, ...
... MAPP ) today announced that the company will,present at ... 2008:, Morgan Stanley Global Healthcare Conference, Key Biscayne, ... Time, Deutsche Bank 33rd Annual Health Care Conference, Boston, ... Time A live webcast of the presentations will be ...
... HILL, N.C., April 25 Managing multi-generational,diversity is ... recent,benchmarking study with 23 leading companies, 80 percent ... and yet only one-third say,their companies offer training ... to download an excerpt of,this new research, The ...
... Today, on World Malaria,Day, the American Red Cross is ... robust global response to this deadly disease., Each ... 300 million people, mostly children in Africa. More,than 1 ... Since 2001, the American Red Cross and its ...
Cached Medicine News:Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 2Health News:Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate 3Health News:Laparoscopic Surgery on Pancreas Has Fewer Complications 2Health News:QLT announces first quarter results for 2008 2Health News:QLT announces first quarter results for 2008 3Health News:QLT announces first quarter results for 2008 4Health News:QLT announces first quarter results for 2008 5Health News:QLT announces first quarter results for 2008 6Health News:QLT announces first quarter results for 2008 7Health News:QLT announces first quarter results for 2008 8Health News:QLT announces first quarter results for 2008 9Health News:QLT announces first quarter results for 2008 10Health News:QLT announces first quarter results for 2008 11Health News:QLT announces first quarter results for 2008 12Health News:QLT announces first quarter results for 2008 13Health News:QLT announces first quarter results for 2008 14Health News:MAP Pharmaceuticals to Present at Upcoming Investor Conferences 2Health News:Multi-generational Diversity Top Challenge for Businesses Today: Leading Company to Share Insights June 4-6 2Health News:Uniting to Fight Malaria Around the World 2Health News:Uniting to Fight Malaria Around the World 3
Two prong stainless steel tips; with titanium handle/...
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
12mm from bend to 0.12mm 1x2 teeth; In Titanium....
Straight Shafts with 0.12mm 1X2 Teeth With 5mm Tying Platform; In Titanium...
Medicine Products: